© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
By year’s end, a new crop of interferon-free hepatitis C combination therapies will likely hit the market.
Victrelis (boceprevir), Merck’s hepatitis C virus (HCV) protease inhibitor, should not be combined with the following Norvir (ritonavir)...
The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)-boosted p...
People taking once-daily Norvir (ritonavir)-boosted Prezista (darunavir) monotherapy were able to maintain control over HIV for 96 week...
People coinfected with HIV and hepatitis C virus (HCV) who receive Viramune (nevirapine) may respond better to pegylated interferon/ribavirin...
The U.S. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents has come nearly full circle...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
